These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34171435)

  • 1. Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine.
    Clayton-Chubb D; Schneider D; Freeman E; Kemp W; Roberts SK
    J Hepatol; 2021 Nov; 75(5):1249-1250. PubMed ID: 34171435
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine.
    Nasuelli NA; De Marchi F; Cecchin M; De Paoli I; Onorato S; Pettinaroli R; Savoini G; Godi L
    Neurol Sci; 2021 Nov; 42(11):4747-4749. PubMed ID: 34272622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxford-AstraZeneca ChAdOx1 COVID-19 Vaccine Does Not Alter Platelet Aggregation.
    Limami Y; Khalki L; Zaid N; Khyatti M; Turk JE; Ammara M; Mtairag EM; Oudghiri M; Naya A; Taberkant M; Zaid Y
    Semin Thromb Hemost; 2022 Feb; 48(1):109-111. PubMed ID: 33971677
    [No Abstract]   [Full Text] [Related]  

  • 4. Onset/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca/Covishield): Report of two cases.
    Nagrani P; Jindal R; Goyal D
    Dermatol Ther; 2021 Sep; 34(5):e15085. PubMed ID: 34350668
    [No Abstract]   [Full Text] [Related]  

  • 5. Exuberant lichenoid eruption after Oxford-AstraZeneca COVID-19 vaccine: a singular case.
    Correia C; Fernandes S; Soares-de-Almeida L; Filipe P
    J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):e268-e270. PubMed ID: 34913207
    [No Abstract]   [Full Text] [Related]  

  • 6. Inverse lichen planus post Oxford-AstraZeneca COVID-19 vaccine.
    Awada B; Abdullah L; Kurban M; Abbas O
    J Cosmet Dermatol; 2022 Mar; 21(3):883-885. PubMed ID: 34997985
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca COVID-19 vaccine.
    Maher DI; Hogarty D; Ben Artsi E
    Orbit; 2023 Dec; 42(6):630-634. PubMed ID: 35499172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed cutaneous reaction to ChAdOx1 nCoV-19 vaccine: Is it an 'AstraZeneca arm'?
    Kim JE; Lee H; Paik SS; Moon JY; Yoon HJ; Kim SH
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):e711-e714. PubMed ID: 34166540
    [No Abstract]   [Full Text] [Related]  

  • 9. Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster.
    Hung IFN; Poland GA
    Lancet; 2021 Mar; 397(10277):854-855. PubMed ID: 33676614
    [No Abstract]   [Full Text] [Related]  

  • 10. Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine.
    Žagar T; Hlača N; Brajac I; Prpić-Massari L; Peternel S; Kaštelan M
    Br J Dermatol; 2022 Mar; 186(3):e110. PubMed ID: 34817862
    [No Abstract]   [Full Text] [Related]  

  • 11. Branch retinal vein occlusion following ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine.
    Karageorgiou G; Chronopoulou K; Georgalas I; Kandarakis S; Tservakis I; Petrou P
    Eur J Ophthalmol; 2023 Sep; 33(5):NP121-NP123. PubMed ID: 36062592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of
    Chhabra N; George A
    Curr Drug Saf; 2023 Apr; 18(4):584-588. PubMed ID: 35702789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.
    Paris C; Perrin S; Hamonic S; Bourget B; Roué C; Brassard O; Tadié E; Gicquel V; Bénézit F; Thibault V; Garlantézec R; Tattevin P
    Clin Microbiol Infect; 2021 Nov; 27(11):1699.e5-1699.e8. PubMed ID: 34265462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limb ischemia and pulmonary artery thrombosis after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine: a case of vaccine-induced immune thrombotic thrombocytopenia.
    Jones M; Boisvert A; Landry J; Petrasek PF
    CMAJ; 2021 Jun; 193(24):E906-E910. PubMed ID: 33990339
    [No Abstract]   [Full Text] [Related]  

  • 16. Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine.
    Sønderskov KM; Dinesen PT; Østergaard SD
    Dan Med J; 2021 Mar; 68(5):. PubMed ID: 33870886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune mediated events timely associated with COVID-19 vaccine. A comment on article by Badier, et al.: "IgA vasculitis in adult patients following vaccination by ChadOx1 nCoV-19".
    Hočevar A; Tomšič M
    Autoimmun Rev; 2022 Feb; 21(2):102989. PubMed ID: 34740853
    [No Abstract]   [Full Text] [Related]  

  • 18. Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine.
    Morlidge C; El-Kateb S; Jeevaratnam P; Thompson B
    Kidney Int; 2021 Aug; 100(2):459. PubMed ID: 34119512
    [No Abstract]   [Full Text] [Related]  

  • 19. Possible Risk of Thrombotic Events following Oxford-AstraZeneca COVID-19 Vaccination in Women Receiving Estrogen.
    Soltani Hekmat A; Javanmardi K
    Biomed Res Int; 2021; 2021():7702863. PubMed ID: 34734086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to 'A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine'.
    Martora F; Fabbrocini G; Guerrasio G; Potestio L
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):e141-e142. PubMed ID: 36227123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.